danavorexton

Danavorexton is a small-molecule drug that acts as a selective agonist of the orexin 2 receptor. It is administered intravenously and has been shown in clinical trials to dose-dependently promote wakefulness to a similar degree as modafinil. Danavorexton is under development primarily for the treatment of narcolepsy (including both type 1 and type 2), idiopathic hypersomnia, and sleep apnea syndromes. The drug was developed by Takeda and has received orphan drug designation for narcolepsy. Its mechanism of action involves selectively activating orexin receptor type 2 (OX2R), which plays a key role in regulating wakefulness; this makes it promising for disorders characterized by excessive daytime sleepiness or disrupted sleep-wake cycles[1][4][5][6][7].

Other names

danavorextonTAK-925TAK925TAK 9251-piperidinecarboxylic acid, 3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)-, methyl ester, (2r,3s)-Methyl (2r,3s)-3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylateMethyl (2R,3S)-3-(Methylsulfonyl)Amino]-2-{[(Cis–4–Phenylcyclohexyl)Oxy]Methyl}Piperidine–1–Carboxylate